論文 - 詳細
| RRC ID | 78685 |
|---|---|
| 著者 | Batbayar C, Ishii N, Harimoto N, Yokobori T, Saito H, Gantumur D, Gombodorj N, Erkhem-Ochir B, Muranushi R, Hoshino K, Yamanaka T, Hagiwara K, Tsukagoshi M, Watanabe A, Araki K, Hosouchi Y, Shirabe K. |
| タイトル | High RRN3 expression is associated with malignant characteristics and poor prognosis in pancreatic cancer. |
| ジャーナル | Int J Clin Oncol |
| Abstract |
BACKGROUND:Pancreatic cancer has an extremely poor prognosis and is one of the most chemoresistant cancers. Targeting cancer cell transcriptional complexes may enhance chemotherapy effectiveness. RNA-polymerase I (Pol-I)-mediated transcription is an essential initial step for ribosome biogenesis and is related to cancer cell proliferation. RRN3 is a Pol-I-specific transcription initiation factor. In this study, we aimed to elucidate the function and clinical significance of RRN3 in pancreatic cancer. METHODS:We performed immunohistochemical staining to detect RRN3 protein expression in 96 pancreatic cancer tissues and analyzed the relationship between RRN3 protein expression, clinicopathological factors, and cancer patient prognosis. Moreover, we evaluated RRN3 function in vitro and in vivo using proliferation, invasion, and chemosensitivity assays in PANC-1 and SW1990 cell lines, with/without depleting RRN3 expression. RESULTS:RRN3 was mainly expressed in cancer cell nuclei. High levels of RRN3 expression were associated with Ki-67 expression and shorter overall survival. Additionally, proliferation and invasion ability were decreased when RRN3 was silenced with siRNA, compared to non-targeting siRNA-transfected cells. Chemosensitivity analysis showed that inhibition of RRN3 enhanced the sensitivity of pancreatic cancer cell lines to gemcitabine and paclitaxel. RRN3 siRNA-transfected PANC-1 tumors showed significantly reduced tumor volumes and high gemcitabine sensitivity compared to the control in a mouse xenograft model. CONCLUSION:High levels of RRN3 expression are associated with poor prognosis and cancer malignancy, such as proliferation, invasion ability, and chemosensitivity in pancreatic cancer. RRN3 targeting with anticancer drugs may be a promising therapeutic strategy to overcome refractory pancreatic cancer. |
| 巻・号 | 28(7) |
| ページ | 901-912 |
| 公開日 | 2023-7-1 |
| DOI | 10.1007/s10147-023-02342-w |
| PII | 10.1007/s10147-023-02342-w |
| PMID | 37119370 |
| MeSH | Animals Cell Line, Tumor Cell Proliferation / genetics Gemcitabine Humans Mice Pancreatic Neoplasms* / drug therapy Pancreatic Neoplasms* / genetics Prognosis RNA, Small Interfering / pharmacology RNA, Small Interfering / therapeutic use |
| リソース情報 | |
| ヒト・動物細胞 | PANC-1(RCB2095) |